HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results

Stock News11-18

BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase 3 HERIZON-GEA-01 study. The trial evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as monotherapy or in combination with the PD-1 inhibitor tislelizumab and chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.

CITIC Securities previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, leading to an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 therapies in markets such as the EU and Japan, and the continued progress in key pipelines like BCL-2, BTK CDAC, and CDK4, the firm maintains a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104425713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 09:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104425713","market":"other","top_or_hot":-1,"title":"HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results","media":"Stock News","content":"<p>BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase 3 HERIZON-GEA-01 study. The trial evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as monotherapy or in combination with the PD-1 inhibitor tislelizumab and chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.</p>\n<p>CITIC Securities previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, leading to an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 therapies in markets such as the EU and Japan, and the continued progress in key pipelines like BCL-2, BTK CDAC, and CDK4, the firm maintains a \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | BEIGENE (06160) Opens Over 3% Higher as Phase 3 Clinical Study of Zanidatamab Combined with Tislelizumab and Chemotherapy Shows Positive Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-18 09:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase 3 HERIZON-GEA-01 study. The trial evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as monotherapy or in combination with the PD-1 inhibitor tislelizumab and chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.</p>\n<p>CITIC Securities previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, leading to an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 therapies in markets such as the EU and Japan, and the continued progress in key pipelines like BCL-2, BTK CDAC, and CDK4, the firm maintains a \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1719994722.HKD","symbol_name":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","start_time":0,"source_url":"","article_id":"1104425713","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104425713","pubTimestamp":1763429302,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1588":"回港中概股","BK1161":"生物科技","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","06160":"百济神州","BK1583":"高瓴概念","BK0239":"医药制造","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","ONC":"百济神州","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1500":"做空集合股","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC"},"translate_title":"港股动向|百济神州(06160)高开超3%扎尼达单抗联合替雷利珠单抗和化疗3期临床研究显示积极结果","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"06160":1,"ONC":1},"content_text":"BEIGENE (06160) opened over 3% higher, rising 3.53% to HK$223.2 by the time of reporting, with a trading volume of HK$11.96 million. On November 17, BEIGENE announced positive results from the Phase 3 HERIZON-GEA-01 study. The trial evaluated the efficacy and safety of zanidatamab, a HER2-targeted bispecific antibody, either as monotherapy or in combination with the PD-1 inhibitor tislelizumab and chemotherapy, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including gastric, gastroesophageal junction, and esophageal cancers.\nCITIC Securities previously noted that BEIGENE's zanubrutinib continues to show strong sales growth, leading to an upward revision of its full-year performance guidance. Considering the company's better-than-expected overseas sales of BTK inhibitors, the launch and expansion of PD-1 therapies in markets such as the EU and Japan, and the continued progress in key pipelines like BCL-2, BTK CDAC, and CDK4, the firm maintains a \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104425713","isCrawlerRequest":true}